Literature DB >> 24272889

Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.

Golam Kibria1, Hiroto Hatakeyama, Hideyoshi Harashima.   

Abstract

Multidrug resistance (MDR), the principal mechanism by which many cancers develop resistance to chemotherapy, is one of the major obstacles to the successful clinical treatment of various types of cancer. Several key regulators are responsible for mediating MDR, a process that renders chemotherapeutic drugs ineffective in the internal organelles of target cells. A nanoparticulate drug delivery system (DDS) is a potentially promising tool for circumventing such MDR, which can be achieved by targeting tumor cells themselves or tumor endothelial cells that support the survival of MDR cancer cells. The present article discusses key factors that are responsible for MDR in cancer cells, with a specific focus on the application of DDS to overcome MDR via the use of chemotherapy or macromolecules.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24272889     DOI: 10.1007/s12272-013-0276-2

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  43 in total

1.  Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance.

Authors:  Veronica Lifshitz; Saul J Priceman; Wenzhao Li; Gregory Cherryholmes; Heehyoung Lee; Adar Makovski-Silverstein; Lucia Borriello; Yves A DeClerck; Hua Yu
Journal:  Mol Cancer Ther       Date:  2017-07-17       Impact factor: 6.261

Review 2.  Targeting the tumour stroma to improve cancer therapy.

Authors:  Kenneth C Valkenburg; Amber E de Groot; Kenneth J Pienta
Journal:  Nat Rev Clin Oncol       Date:  2018-06       Impact factor: 66.675

3.  shRNA-mediated silencing of sorcin increases drug chemosensitivity in myeloma KM3/DDP and U266/ADM cell lines.

Authors:  Ping Xu; Yong-Fang Jiang; Jing-Hua Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 4.  The evolving role of DNA inter-strand crosslinks in chemotherapy.

Authors:  Halley B Rycenga; David T Long
Journal:  Curr Opin Pharmacol       Date:  2018-04-18       Impact factor: 5.547

5.  LncRNA RP3-326I13.1 promotes cisplatin resistance in lung adenocarcinoma by binding to HSP90B and upregulating MMP13.

Authors:  Huixin Zhou; Xiaolu Huang; Wenjing Shi; Shihao Xu; Jie Chen; Kate Huang; Yumin Wang
Journal:  Cell Cycle       Date:  2022-03-17       Impact factor: 5.173

6.  The clinical relevance and prognostic significance of adenosine triphosphate ATP-binding cassette (ABCB5) and multidrug resistance (MDR1) genes expression in acute leukemia: an Egyptian study.

Authors:  Hala M Farawela; Mervat M Khorshied; Neemat M Kassem; Heba A Kassem; Hamdy M Zawam
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-08       Impact factor: 4.553

Review 7.  Role of long non-coding RNA in tumor drug resistance.

Authors:  Heng Deng; Jun Zhang; JinJun Shi; ZhengDong Guo; ChunRong He; Li Ding; Jin Hai Tang; Yong Hou
Journal:  Tumour Biol       Date:  2016-07-05

8.  Cell-penetrating peptide conjugates to enhance the antitumor effect of paclitaxel on drug-resistant lung cancer.

Authors:  Ziqing Duan; Cuitian Chen; Jing Qin; Qi Liu; Qi Wang; Xinchun Xu; Jianxin Wang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 9.  Marine natural products as breast cancer resistance protein inhibitors.

Authors:  Lilia Cherigo; Dioxelis Lopez; Sergio Martinez-Luis
Journal:  Mar Drugs       Date:  2015-04-03       Impact factor: 5.118

10.  The effect of radiation exposure on multidrug resistance: in vitro and in vivo studies using non-small lung cancer cells.

Authors:  Shohei Kanno; Keita Utsunomiya; Yumiko Kono; Noboru Tanigawa; Satoshi Sawada
Journal:  EJNMMI Res       Date:  2015-03-17       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.